Monoclonal Antibodies In Veterinary Health Market Anticipated To Witness Robust Growth, Surpassing $1.61 Billion By 2029

The Monoclonal Antibodies In Veterinary Health Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Monoclonal Antibodies In Veterinary Health Market Size and Its Estimated Growth Rate?
In the veterinary health sector, the market size of monoclonal antibodies has seen significant growth in the recent past. It is expected to expand from $0.8 billion in 2024 and reach $0.92 billion by 2025, growing at a compound annual growth rate (CAGR) of 15.2%. The surge in the historical period can be credited to factors such as a rise in global pet ownership, a high incidence of chronic diseases in pets, increased pet adoption rates, and heightened health awareness among pet owners.

The market size for monoclonal antibodies in veterinary health is predicted to experience swift expansion in the coming years. The market is projected to reach $1.61 billion by 2029, with a compound annual growth rate (CAGR) of 15.0%. The growth during this forecasted period can be associated with factors such as an increase in the pet population, elevated spending on pets, the rising occurrence of canine atopic dermatitis, higher demand for sophisticated veterinary healTH*Care, and an increased focus on animal health. Key trends expected during this period include progress in biotechnology and research, advancements in genetic engineering, the development of new treatments, progression in antibody-based therapeutics, and technological innovation in antibody engineering.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20575

How Are Emerging Segments Shaping the Monoclonal Antibodies In Veterinary Health Market Landscape?
The monoclonal antibodies in veterinary health market covered in this report is segmented -

1) By Animal Type: Dogs, Other Animal Types
2) By Application: Dermatology, Pain, Other Applications
3) By End-User: Veterinary Hospitals, Other End-Users

Subsegments:
1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies
2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

Which Growth Factors Are Influencing Monoclonal Antibodies In Veterinary Health Market Expansion?
The anticipated escalation of animal disease rates is expected to drive the expansion of the monoclonal antibodies in the veterinary health market. Factors such as intensified farming methods, which raise the likelihood of infectious disease transmission, and climatic shifts, which widen the habitat of disease carriers like ticks and mosquitoes, contribute to the surge in animal diseases. Monoclonal antibodies, which pinpoint specific pathogens or proteins involved in disease progression, serve as highly effective treatments for animal diseases. For example, between April 2023 and March 2024, as reported by GOV.UK, a UK government website, there was a 5% increase in animals slaughtered due to TB incidents in England, totalling 21,298, and a 17% increase in Wales, amounting to 11,197. The surge in animal disease rates is fuelling the expansion of the monoclonal antibodies in the veterinary health market.

Who Are the Dominant Players Across Different Monoclonal Antibodies In Veterinary Health Market Segments?
Major companies operating in the monoclonal antibodies in veterinary health market are Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Bio-Rad Laboratories Inc., Eli Lilly and Company, GenScript Biotech Corporation, Abcam plc, Heska Corporation, Neogen Corporation, iNova Pharmaceuticals, Ceva Santé Animale S.A., Biogénesis Bagó S.A., TransGen Biotech Co. Ltd., AbCellera Biologics Inc., Areteia Therapeutics Inc., Esco Aster Pte Ltd, PetMedix Ltd., Vaxine Pty Ltd

What Are the Latest Developing Trends in the Ambulatory X-Ray Devices Market?
Key players in the monoclonal antibodies in veterinary health market are channeling their focus towards creating groundbreaking veterinary therapies such as anti-NGF monoclonal antibody solutions. These solutions are targeting the treatment of chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment signifies a therapeutic method geared towards inhibiting nerve growth factor (NGF), thereby easing pain and inflammation in animals plagued with chronic pain. For instance, in May 2023, Zoetis, an American animal health firm, gained FDA approval for its Librela (bedinvetmab injection), registering it as the pioneer monoclonal antibody treatment developed explicitly for managing osteoarthritic pain in dogs. The Librela medication, administered through monthly injections, works by targeting and inhibiting NGF. Furthermore, Zoetis launched Apoquel Chewable, the first chewable drug designed for controlling allergic itch and inflammation in dogs above one year old. With its capacity to block NGF, Librela reduces pain perception by stopping pain signals from reaching the brain. This groundbreaking achievement marks a significant step forward in the management of pain in the veterinary sector, ushering in a fresh perspective in treating chronic pain in dogs.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

Which Geographic Regions Are Expected to Dominate the Monoclonal Antibodies In Veterinary Health Market in the Coming Years?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Monoclonal Antibodies In Veterinary Health Market?
2. What is the CAGR expected in the Monoclonal Antibodies In Veterinary Health Market?
3. What Are the Key Innovations Transforming the Monoclonal Antibodies In Veterinary Health Industry?
4. Which Region Is Leading the Monoclonal Antibodies In Veterinary Health Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the monoclonal antibodies in veterinary health market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.